Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Research & Development: 2010-2025

Historic Research & Development for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $3.3 million.

  • Lineage Cell Therapeutics' Research & Development rose 3.15% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 0.32%. This contributed to the annual value of $12.5 million for FY2024, which is 20.59% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Research & Development of $3.3 million as of Q3 2025, which was up 5.31% from $3.1 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Research & Development's 5-year high stood at $24.8 million during Q4 2021, with a 5-year trough of $2.8 million in Q3 2021.
  • For the 3-year period, Lineage Cell Therapeutics' Research & Development averaged around $3.4 million, with its median value being $3.3 million (2025).
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Research & Development surged by 850.44% in 2021, and later crashed by 83.44% in 2022.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Research & Development stood at $24.8 million in 2021, then tumbled by 83.44% to $4.1 million in 2022, then dropped by 4.82% to $3.9 million in 2023, then decreased by 12.37% to $3.4 million in 2024, then rose by 3.15% to $3.3 million in 2025.
  • Its Research & Development stands at $3.3 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.1 million for Q1 2025.